Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial

Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Edward N. Libby, III, MD, Mary Philip, MD PhD, Margaret E. Nartea, Christen N. Heye, ARNP, Sandra L. Kanan, ARNP, Sanaz Behnia, MD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2806.

https://doi.org/10.1182/blood.V130.Suppl_1.2806.2806

Published: 2017

Journal Articles

Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial

Ryan D Cassaday, MD, Jonathan Fromm, MD PhD, Andrew J. Cowan, MD, Edward N. Libby, III, MD, Mary Philip, MD PhD, Sanaz Behnia, MD, Margaret Nartea, Oliver Press, Ajay K Gopal, MD

Blood (2016) 128 (22): 1834.

https://doi.org/10.1182/blood.V128.22.1834.1834

Published: 2016

Journal Articles

Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer

Mary Philip, MD PhD, Lauren Fairchild, Liping Sun, PhD, Agnes Viale, PhD, Taha Merghoub, PhD, Jedd D. Wolchok, MD PhD, Christina S. Leslie, PhD, Andrea Schietinger, PhD

Blood (2016) 128 (22): 861.

https://doi.org/10.1182/blood.V128.22.861.861

Published: 2016

Journal Articles

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Solomon A. Graf, MD, Philip A. Stevenson, MS, Leona A. Holmberg, MD PhD, Brian G. Till, MD, Oliver W. Press, MD PhD, Thomas R. Chauncey, MD PhD, Stephen D. Smith, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, MD, William I. Bensinger, MD, John M. Pagel, MD PhD, David G Maloney, MDPhD, Yi Zhou, MD PhD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3985.

https://doi.org/10.1182/blood.V124.21.3985.3985

Published: 2014

Journal Articles

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Theodore A. Gooley, PhD, Thomas Chauncey, MD PhD, John Pagel, MD PhD, Brian G. Till, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, William I. Bensinger, MD, Leona Holmberg, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Stephen D. Smith, MD, Edward N. Libby, MD, David G Maloney, MDPhD, Lorinda A. Soma, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3967.

https://doi.org/10.1182/blood.V124.21.3967.3967

Published: 2014

Journal Articles

Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis

Anna Houk, BS, MS1, Ajay K. Gopal, MD, Edward N. Libby, MD, Andrei R. Shustov, MD, Damian J. Green, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, David G Maloney, MDPhD, Oliver W. Press, MD PhD, Stephen D. Smith, MD

Blood (2014) 124 (21): 3086.

https://doi.org/10.1182/blood.V124.21.3086.3086

Published: 2014

Journal Articles

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Bronwyn H. Bryant, MD, Cecilia Yeung, MD, Brian G. Till, MD, Stephen D. Smith, MD, Edward N. Libby, MD, Andrei R. Shustov, MD, John M. Pagel, MD PhD, Damian J. Green, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Min Fang, MD PhD, Leona Holmberg, MD PhD, William I. Bensinger, MD, David G Maloney, MDPhD, Ajay K. Gopal, MD, Oliver W. Press, MD PhD

Blood (2014) 124 (21): 1731.

https://doi.org/10.1182/blood.V124.21.1731.1731

Published: 2014

Journal Articles

Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status

Maika Onishi, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Karen Schiavo, ARNP, Mary Philip, MD, PhD, Edward N. Libby, III, MD, Ryan D. Cassaday, MD, John M. Pagel, MD, PhD, David G. Maloney, MD, PhD, Damian J. Green, MD, Brian G. Till, MD, Oliver W. Press, MD, PhD, Ajay K. Gopal, MD

Blood (2013) 122 (21): 2106.

https://doi.org/10.1182/blood.V122.21.2106.2106

Published: 2013

Journal Articles

FLVCR, a Heme Exporter, Is Required for Peripheral T Cell Survival.

Mary Philip, MD, PhD, Scott A. Funkhouser, BS, Jeff J. Delrow, PhD, Edison Y. Chiu, BA, Janis L Abkowitz, MD

Blood (2012) 120 (21): 2162.

https://doi.org/10.1182/blood.V120.21.2162.2162

Published: 2012

Journal Articles

Full Dose Bendamustine (Treanda ®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma

Lihua Elizabeth Budde, MD, PhD, Shustov R Andrei, M.D., Gooley Ted, Ph.D., Tara L Chen, PharmD, BCOP, Edward N. Libby, III, MD, Maria Corinna Palanca-Wessels, M.D., Ph.D., Mary Philip, MD, PhD, Daniel B. Martin, M.D., Ryan D. Cassaday, MD, Kiarash Kojouri, MD, MPH, Oliver W. Press, MD, PhD, Ajay K. Gopal, MD

Blood (2012) 120 (21): 3650.

https://doi.org/10.1182/blood.V120.21.3650.3650

Published: 2012

Journal Articles

Why Do Erythroid Cells Need to Export Heme?

Janis L. Abkowitz, MD, Sioban B Keel, MD, Mary Philip, MD PhD, John C Byon, MD PhD, Raymond T Doty, PhD

Blood (2011) 118 (21): SCI-24.

https://doi.org/10.1182/blood.V118.21.SCI-24.SCI-24

Published: 2011

Journal Articles

Regulation of Flvcr by Macrophages in Response to Lipopolysaccharide

Mary Philip, MD PhD, Edison Y. Chiu, Janis L. Abkowitz, MD

Blood (2011) 118 (21): 2111.

https://doi.org/10.1182/blood.V118.21.2111.2111

Published: 2011

Journal Articles

Heme Metabolic Gene Expression In FLVCR-Knockout Mice During T Cell Development

Mary Philip, MD, PhD, Alexandra R. Zaballa, Blake T. Hovde, BS, Janis L. Abkowitz, MD

Blood (2010) 116 (21): 2787.

https://doi.org/10.1182/blood.V116.21.2787.2787

Published: 2010

Journal Articles

Loss of FLVCR, a Heme Export Protein, Blocks Thymic T Cell Development at the CD4 + CD8 + Double-Positive Stage.

Mary Philip, MD, PhD, Jing Chen, MD, Raymond T Doty, PhD, Janis L. Abkowitz, MD

Blood (2009) 114 (22): 913.

https://doi.org/10.1182/blood.V114.22.913.913

Published: 2009

NARROW

Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial

Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial

Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status

FLVCR, a Heme Exporter, Is Required for Peripheral T Cell Survival.

Full Dose Bendamustine (Treanda ®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma

Why Do Erythroid Cells Need to Export Heme?

Regulation of Flvcr by Macrophages in Response to Lipopolysaccharide

Heme Metabolic Gene Expression In FLVCR-Knockout Mice During T Cell Development

Loss of FLVCR, a Heme Export Protein, Blocks Thymic T Cell Development at the CD4 + CD8 + Double-Positive Stage.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only